mRNA-1273 Covid-19 Vaccine will be charged $25-$37: Moderna

Moderna is proud to be among the many groups working to respond to this continuing global health emergency. The mRNA-1273 is their vaccine candidate against the novel coronavirus. 

Recently, CEO of Moderna, Stephane Bancel told "Moderna will charge governments between $25 and $37 per dose of its Covid-19 vaccine candidate, depending on the amount ordered and Our vaccine therefore costs about the same as a flu shot, which is between $10 and $50,"

"Nothing is signed yet, but we're close to a deal with the EU Commission. We want to deliver to Europe and are in constructive talks, adding it was just a "matter of days" until a contract would be ready"- He said.

 

 More Information About This Vaccine

As per the Moderna, its experimental vaccine is 94.5% effective in preventing Covid-19.

Moderna’s Covid-19 vaccine, mRNA-1273, looks set to be one of the leading vaccines by sales in 2026 according to Q2 2020 forecasts from GlobalData’s Pharma Intelligence Center, Drug Sales and Consensus Forecast database. 

The Company’s plans to seek regulatory approval for the use of mRNA-1273 in the U.S. and other jurisdictions,the conditions under which mRNA-1273 can be shipped, stored and administered,the Company’s sales of mRNA-1273 and the status of negotiations for such sales, and the Company’s anticipated production ofmRNA-1273.

Phase 3 study met statistical criteria with a vaccine efficacy of 94.5%

→Primary endpoint of the Phase 3 COVE study is based on the analysis of COVID - 19 cases confirmed and adjudicated  starting two weeks following the second dose of vaccine.

→Based on 95 cases, of which 90 cases of COVID - 19 were observed in the placebo group versus 5 cases observed in  the mRNA - 1273 group, resulting in a point estimate of vaccine efficacy of 94.5% (p <0.0001).

→Secondary endpoint analyzed severe cases of COVID - 19 and included 11 severe cases (as defined in the study protocol).

→ All 11 cases occurred in the placebo group and none in the mRNA - 1273 vaccinated group.

→The 95 COVID - 19 cases included 15 older adults (ages 65+) and 20 participants identifying as being from diverse  communities (including 12 Hispanic or  LatinX , 4 Black or A frican A mericans, 3 A sian A mericans and 1 multiracial).

 

Safety Concern

A  review of solicited adverse events demonstrated that vaccine was generally  well  tolerated; majority of adverse events  were mild or moderate in severity and the solicited adverse events were generally short lived. Grade 3 (severe) events greater than or equal to 2% in frequency after the first dose included injection site pain  (2.7%), and after the second dose included fatigue (9.7%), myalgia (8.9%), arthralgia (5.2%), headache (4.5%), pain  (4.1%) and erythema/red. 

Related Posts

Share this post

Subscribe Our Newsletter